DTaP-hepatitis B-poliovirus vaccine - GlaxoSmithKline

Drug Profile

DTaP-hepatitis B-poliovirus vaccine - GlaxoSmithKline

Alternative Names: Infanrix PeNta; Infanrix-HepB-IPV; InfanrixDTPa®-HepB-IPV; Pediarix

Latest Information Update: 23 Jan 2008

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Nonindustrial source
  • Class Bacterial vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Hepatitis B; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 09 Jan 2003 Launched for Poliomyelitis in USA (IM)
  • 09 Jan 2003 Launched for Pertussis in USA (IM)
  • 09 Jan 2003 Launched for Hepatitis B in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top